COMMON STOCK PURCHASE WARRANT northwest biotherapeutics, inc.Common Stock Purchase Warrant • August 7th, 2017 • Northwest Biotherapeutics Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 7th, 2017 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business at 5:00 p.m. (New York City time) on _____1 (the “Termination Date) but not thereafter, to subscribe for and purchase from Northwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Re: Reset Offer of Common Stock Purchase WarrantsReset Offer of Common Stock Purchase Warrants • August 7th, 2017 • Northwest Biotherapeutics Inc • Pharmaceutical preparations
Contract Type FiledAugust 7th, 2017 Company IndustryNorthwest Biotherapeutics, Inc. (the “Company”) is pleased to offer to you the opportunity to reprice the exercise of all of the Common Stock purchase warrants set forth on Annex I attached hereto (the “Existing Warrants”) currently held by you (“Holder”). The Existing Warrants and the shares of Common Stock underlying the Existing Warrants (“Warrant Shares”) have been registered for sale pursuant to a registration statement on Form S-3 (File No. 333-213777) (the “Registration Statement”). The Registration Statement is currently effective and, at the time of exercise of the Existing Warrants pursuant to this letter agreement, will be effective for the issuance of all of the Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Securities Purchase Agreement, dated as of March 17, 2017, by and among the Company and the signatories thereto (the “Purchase Agreement”).